Alaunos Therapeutics Inc. stocks have been trading up by 137.14 percent amid highly positive sentiment from recent oncology pipeline headlines.
Click Here for a Millionaire's POV on Trading TCRT
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Intraday action shows TCRT exploding from around $1 to above $2.50 in premarket, signaling aggressive speculative trading and heavy momentum.
- Recent daily chart data for Alaunos Therapeutics Inc. shows the stock rebounding off sub-$0.80 levels after a steady pullback from the $1.60 area.
- Financials highlight minimal revenue, steep losses, and tight cash, making TCRT a classic high-risk, story-driven biotech trading vehicle.
- Alaunos Therapeutics Inc. carries negative returns on equity and assets, but a debt-free capital structure gives traders a cleaner read on dilution and cash burn risk.
Live Update At 07:46:46 EDT: On Tuesday, October 13, 2026 Alaunos Therapeutics Inc. stock [NASDAQ: TCRT] is trending up by 137.14%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
TCRT is trading like a pure biotech speculation play, and the numbers back that up. Alaunos Therapeutics Inc. posted just about $5,000 in revenue, yet the market is valuing that tiny top line at a huge multiple, with a price-to-sales ratio near 957. That tells traders this is not about current sales; it is about hope, pipeline value, and momentum.
Profitability for TCRT is deeply negative. Pretax margins are around -3,347%, and return on equity sits near -169%. Return on assets is even worse. Alaunos Therapeutics Inc. is losing money fast, and the income statement shows a quarterly net loss of about $952,000 on minimal revenue. Basic EPS is roughly -$0.41.
More Breaking News
- DAIC Stock Slides As Losses Mount And Liquidity Tightens
- SOFI Stock Slips As Analysts Flag $1B Q3 Headwind
- SCNI Stock Holds Nasdaq Compliance As Trading Volatility Spikes
- YJ Stock Climbs As Traders Zero In On Breakout Setup
On the balance sheet, TCRT holds only about $124,000 in cash against total liabilities of $864,000, with a current ratio of 0.8 and quick ratio of 0.1. That is tight. The company has no long-term debt, but working capital is negative. For traders, Alaunos Therapeutics Inc. looks like a classic “cash runway plus dilution risk” scenario that can still offer powerful trading spikes when volume rushes in.
Why Traders Are Watching TCRT’s Price Action
TCRT is lighting up the screens today because of its extreme volatility. In the intraday data, Alaunos Therapeutics Inc. ramps from roughly $1.00 at 07:00 to the $2.50 area by 07:45, with huge wicks and wide ranges on every five-minute candle. That is the kind of chaotic premarket action momentum traders dream about. The 07:20 candle alone shows a range from $1.54 to $2.16 before closing at $1.86, then TCRT immediately rips higher on the next few bars.
Zooming out, the daily chart shows Alaunos Therapeutics Inc. was trading in the $1.20–$1.60 range around 2026/09/18, then slid down into the $0.78–$0.90 zone by early October. That steady bleed scared out weak hands. Now TCRT has bounced sharply from a recent close near $0.79–$0.82 back to $1.05 on 2026/10/12, and the intraday surge above $2 premarket screams short-covering plus fresh speculative money.
For day traders, this is a clean pattern: a beaten-down biotech with terrible fundamentals, tiny revenue, and heavy losses suddenly catching massive liquidity. Alaunos Therapeutics Inc. has all the hallmarks of a low-float momentum runner where technicals trump fundamentals in the short term. The key now is how TCRT trades around whole-dollar levels like $2 and $1.50. Breaks and fails at those lines often define the best long and short opportunities for disciplined traders.
Conclusion
TCRT sits at the intersection of ugly fundamentals and beautiful volatility. Alaunos Therapeutics Inc. is burning cash, generating almost no revenue, and posting brutal returns on equity and assets. The balance sheet shows only $124,000 in cash and negative working capital. From a long-term fundamental angle, that is a serious red flag. But traders in this niche are not hunting safe balance sheets; they are hunting range, liquidity, and emotion.
Right now, TCRT is delivering exactly that. A move from under $1 to above $2.50 in less than an hour of premarket trading is a textbook momentum wave. For Alaunos Therapeutics Inc., every sharp spike like this tends to open the door to secondary offerings, dilution risk, or sharp reversals. That is why experienced traders in the Tim Sykes community lean on strict rules. As Tim Bohen, lead trainer with StocksToTrade says, “Time and experience have taught me that missed opportunities are part of the game. There’s always another setup around the corner.” For TCRT, that means traders do not need to chase every spike; they can wait patiently for clean, high-probability setups.
As Tim Sykes loves to remind traders, “I’m not always right, but I always cut losses quickly.” TCRT demands that mindset. Alaunos Therapeutics Inc. can reward nimble traders who plan their entries around clear intraday levels and honor their exits without hesitation. Treat TCRT as a trading vehicle, not a comfort stock, and always remember this is educational and research-focused analysis, not advice to buy or sell.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.